8-K: Jasper Therapeutics Announces Positive Clinical Data and Third Quarter 2024 Financial Results

Jasper Therapeutics reported positive initial data from its SPOTLIGHT study in chronic inducible urticaria, along with third quarter financial results and a corporate update.

Summary

• Jasper Therapeutics announced positive preliminary results from its SPOTLIGHT study, showing that over 90% of patients in the 40mg and 120mg dose cohorts achieved a clinical response.
• The company also reported no serious adverse events or grade 3 or higher adverse events in the SPOTLIGHT study.
• Regulatory clearance was obtained to enroll a 180mg dose cohort in the SPOTLIGHT study, and full data is expected in the first half of 2025.
• The BEACON study in chronic spontaneous urticaria has completed enrollment for a 360mg single-dose cohort, with initial data expected in the week of January 6th, 2025.
• An open-label extension study for chronic urticarias will roll over patients from the BEACON and SPOTLIGHT studies.
• Regulatory clearance was received in Canada and the EU for a Phase 1b/2a asthma challenge study, with patient enrollment commenced and dosing expected in the fourth quarter of 2024.
• A Phase 1 trial in lower-risk myelodysplastic syndromes (LR-MDS) showed briquilimab depleted diseased hematopoietic stem cells but did not improve hematopoiesis, leading to discontinuation of development in this indication.
• Cash and cash equivalents totaled $92.5 million as of September 30, 2024.
• Research and development expenses for the quarter were $14.5 million, and general and administrative expenses were $5.4 million.
• The company reported a net loss of $18.6 million, or $1.24 per share, for the quarter ended September 30, 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data, particularly from the SPOTLIGHT study, and the company has a strong cash position. The discontinuation of the LR-MDS program is a minor negative, but the overall tone is optimistic and suggests a positive outlook for the company's future.

Positives

• The SPOTLIGHT study showed very high clinical response rates in patients with cold urticaria and symptomatic dermographism.
• Briquilimab demonstrated a strong safety profile in the SPOTLIGHT study.
• The company has expanded its clinical programs with higher dose cohorts and regulatory clearances.
• The asthma challenge study has commenced enrollment and is expected to provide proof-of-concept data.
• The company has a solid cash position of $92.5 million.

Negatives

• The Phase 1 trial in LR-MDS did not show improvement in hematopoiesis, leading to discontinuation of development in that indication.
• The company reported a net loss of $18.6 million for the quarter.

Risks

• Clinical trials may not confirm the safety or efficacy of briquilimab.
• Prior study results may not be replicated in future studies.
• The company may not be able to successfully market or gain market acceptance of its product candidates.
• The company is subject to risks related to general economic, political, and business conditions.
• The company is dependent on third parties for laboratory, clinical development, and manufacturing services.

Future Outlook

The company anticipates presenting initial data from the BEACON study in the week of January 6th, 2025, full data from the SPOTLIGHT study in the first half of 2025, and initial data from the asthma challenge study in the second half of 2025. They also plan to continue advancing their clinical programs.

Management Comments

• We achieved several significant milestones in our mast cell development programs in recent months, highlighted by positive initial data from our SPOTLIGHT study in CIndU, said Ronald Martell, President and Chief Executive Officer of Jasper.
• We were very excited to present our first dataset evaluating briquilmab in a mast cell disease, which showed that over 90% of patients treated in the 40mg and 120mg dose cohorts achieved a clinical response, with no serious adverse events (SAEs) and no grade 3 or higher adverse events (AEs) reported.

Industry Context

This announcement is significant in the biotechnology industry as it highlights positive clinical data for a novel antibody therapy targeting mast cell driven diseases, which are areas of unmet medical need. The results position Jasper as a potential player in the treatment of chronic urticaria and asthma.

Comparison to Industry Standards

• The 90% clinical response rate in the SPOTLIGHT study is very promising compared to existing treatments for chronic inducible urticaria, which often have lower response rates and more side effects.
• The safety profile of briquilimab, with no serious adverse events reported, is also a positive differentiator compared to some other therapies in this space.
• Companies like Xolair (omalizumab) by Novartis and Genentech are established players in the urticaria market, but briquilimab's novel mechanism of action could offer a new treatment option.
• The development of briquilimab as a conditioning agent for stem cell transplants also positions Jasper in a competitive space with companies like Gamida Cell and others developing cell therapies.

Stakeholder Impact

• Shareholders may react positively to the strong clinical data and the company's cash position.
• Patients with chronic urticaria and asthma may benefit from the development of briquilimab.
• Employees may be motivated by the positive progress of the company's clinical programs.
• Suppliers and partners may see increased business opportunities with the company's growth.

Next Steps

• Present full data from the SPOTLIGHT study in the first half of 2025.
• Present initial data from the BEACON study during the week of January 6th, 2025.
• Present initial data from the asthma challenge study in the second half of 2025.
• Continue patient enrollment in the 180mg dose cohort of the SPOTLIGHT study.
• Continue patient enrollment and dosing in the asthma challenge study.

Key Dates

Keywords

briquilimab, chronic urticaria, asthma, mast cell, clinical trial, SPOTLIGHT study, BEACON study, regulatory clearance, hematopoietic stem cells, biotechnology